Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 5/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27447806 | 0.84 | KMT2A (0.54) | HSD17B2HSD17B1GPBAR1CES2CES1 | |
| SCHEMBL7455084 | 0.82 | HSD17B2 (0.47) | HSD17B2OPRD1PDK1PDK2PDK3 | |
| SCHEMBL6310719 | 0.81 | ATM (0.51) | HSD17B2PDK1PDK2PDK3PDK4 | |
| SCHEMBL4576119 | 0.80 | UNG (0.47) | HSD17B2OPRD1PDK1PDK2PDK3 | |
| SCHEMBL4250786 | 0.79 | HTR3E (0.49) | HSD17B2HSD17B1GRM1GPBAR1CES2 | |
| SCHEMBL2086375 | 0.79 | ERN1 (0.46) | ALDH1A1HPGD | |
| SCHEMBL21620316 | 0.78 | ALDH1A1 (0.47) | HSD17B2GPBAR1KDM1AMAOAMAOB | |
| SCHEMBL27439157 | 0.77 | HSD17B2 (0.51) | HSD17B2OPRD1PDK1PDK2PDK3 | |
| SCHEMBL255000 | 0.76 | CES2 (0.61) | GRM1CES2CES1OPRM1OPRL1 | |
| SCHEMBL29482201 | 0.76 | CES2 (0.61) | GRM1CES2CES1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501513-B1 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | VERSI GROUP LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476280-B2 | Modulate contraction, relaxation of muscles | VERSI GROUP, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| CN-100508980-C | Compositions for combating lower urinary tract dysfunctions with delta opioid receptor agonists | MOUNT COOK BIOSCIENCES INC (US) | 2009-07-08 | — | — | CN | disclosed |
| CN-1652787-A | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | ARDENT PHARMACEUTICALS INC (US) | 2005-08-10 | — | — | CN | disclosed |
| EP-1501513-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | Ardent Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | VERSI GROUP, LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003094853-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | OPRD1, OPRK1, OPRM1 | HSD17B2 413/4885OPRD1 1/4885SCN2A 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.